Open AccessDetection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report
Author(s) -
Ke-Hui Ren,
Qin Wenwen,
Yun Wang,
Jingcui Peng,
Wenxia Hu
Publication year - 2022
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm-22-744
Subject(s) - osimertinib , t790m , medicine , erlotinib , gefitinib , anaplastic lymphoma kinase , epidermal growth factor receptor , cancer research , lung cancer , tyrosine kinase , erlotinib hydrochloride , tyrosine kinase inhibitor , oncology , cancer , receptor , malignant pleural effusion
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom